Drug Profile
Lefradafiban
Alternative Names: BIBU 104; BIBU 104XXLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antiplatelets; Biphenyl compounds; Pyrrolidines; Small molecules
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Thrombosis; Unstable angina pectoris
Most Recent Events
- 13 Jun 2001 Discontinued-II for Myocardial infarction in Europe (PO)
- 13 Jun 2001 Discontinued-II for Thrombosis in Germany (PO)
- 13 Jun 2001 Discontinued-II for Unstable angina pectoris in Europe (PO)